BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 29113030)

  • 1. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
    Lee EW; Khan S
    Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.
    Vogl TJ; Gruber-Rouh T
    Dig Dis Sci; 2019 Apr; 64(4):959-967. PubMed ID: 30835030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
    Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
    J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts in embolotherapy of HCC.
    Pesapane F; Nezami N; Patella F; Geschwind JF
    Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization.
    Manas D; Bell JK; Mealing S; Davies H; Baker H; Holmes H; Hubner RA
    Eur J Surg Oncol; 2021 Feb; 47(2):401-408. PubMed ID: 32958370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 10. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments.
    Gnutzmann D; Kortes N; Sumkauskaite M; Schmitz A; Weiss KH; Radeleff B
    Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):69-80. PubMed ID: 29381102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transarterial ablative therapy of hepatocellular carcinoma].
    Mahnken AH
    Radiologe; 2014 Jul; 54(7):685-93. PubMed ID: 25047524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study).
    Hirsch RD; Mills C; Sawhney R; Sood S; Bird V; Mishra G; Dev A; Kemp W; Lubel J; Roberts SK; Gow P; Nicoll AJ
    J Gastrointest Cancer; 2021 Sep; 52(3):907-914. PubMed ID: 32901445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoembolization and radioembolization.
    Sangro B
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):909-19. PubMed ID: 25260317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization for the treatment of hepatocellular carcinoma.
    Kim HC
    Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
    Minocha J; Salem R; Lewandowski RJ
    Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.